Embase (169)
Database: Embase <1988 to 2018 Week 07> Search Strategy: (169) 2.13.18 Scopus (235) ( ( ( TITLE-ABS-KEY ( "systolic heart failure" OR "heart failure" ) ) AND ( TITLE-ABS-KEY ( "catheter ablation" ) ) AND ( TITLE-ABS-KEY ( "atrial fibrillation" ) ) ) AND ( TITLE-ABS-KEY ( "meta-analysis" OR "systematic review" ) ) ) OR ( ( ( TITLE-ABS-KEY ( "systolic heart failure" OR "heart failure" ) ) AND ( TITLE-ABS-KEY ( "catheter ablation" ) ) AND ( TITLE-ABS-KEY ( "atrial fibrillation" ) ) ) AND ( ( TITLE-ABS-KEY ( "clinical trial" ) AND TITLE-ABS-KEY ( "phase II" OR "phase III" OR "phase 2" OR "phase 3" ) ) ) ) OR ( ( ( TITLE-ABS-KEY ( "systolic heart failure" OR "heart failure" ) ) AND ( TITLE-ABS-KEY ( "catheter ablation" ) ) AND ( TITLE-ABS-KEY ( "atrial fibrillation" ) ) ) AND ( TITLE-ABS-KEY ( "randomized controlled trial" OR rct ) AND PUBYEAR > 1999 ) ) AND ( EXCLUDE ( PUBYEAR , 1996 ) 
Web of Science (109)
TOPIC: ("heart failure" OR "systolic heart failure") AND TOPIC: ("atrial fibrillation") AND TOPIC: ("catheter ablation" OR "pulmonary vein isolation") Indexes=SCI-EXPANDED, ESCI Timespan=All years AND TOPIC: ("randomized controlled trial" OR RCT) OR TOPIC: ("clinical trial") AND TOPIC: ("phase II" OR "phase 2" OR "phase III" OR "phase 3") OR TOPIC: ("systematic review" OR "meta-analysis") Indexes=SCI-EXPANDED, ESCI Timespan=All years 2.13.18 Cochrane Database of Systematic Reviews/Controlled Clinical Trials (91) Database: EBM Reviews -Cochrane Central Register of Controlled Trials <January 2018>, EBM ReviewsCochrane Database of Systematic Reviews <2005 to February 9, 2018> Search Strategy: 
5
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).

METHODS
Protocol and registration
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
5
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
6
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
7
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Summary measures
13 State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results
14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis.
8-9
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
9
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
9
Study characteristic s 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
10
Risk of bias within studies
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
10-12
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.
Risk of bias across studies eFigure. 9A&B-Sensitivity analysis for change in ejection fraction. The Sensitivity analysis was performed by removing the studies that reported the smallest (top) and the largest (below) difference in outcome.
